IFF at Barclays consumer conference: turnaround gains traction

IFF said leverage has fallen to 2.5x from 4.5x since early 2024 and expects roughly $3.8 billion of proceeds from the Food Ingredients divestiture, targeted for completion in H1 2025. Management has already authorized a $2.5 billion buyback, plans to maintain 2.0x-2.5x leverage, and is increasingly confident in meeting full-year guidance after second-quarter growth accelerated across Scent, Taste, and Health & Biosciences. IFF targets mid-single-digit normalized sales growth, though it expects low-single-digit growth in the second half and cited weak North American probiotics, tariffs, oil prices, and geopolitical volatility as risks.

Analysis

IFF’s investable inflection is the conversion from a balance-sheet-repair story into a higher-quality specialty-ingredients compounder. The key valuation question is whether the remaining portfolio can sustain mid-single-digit organic growth while expanding margins; if so, the market should narrow IFF’s historical discount to Givaudan (GIVN) and DSM-Firmenich (DSFIR). The announced repurchase authorization is potentially material relative to equity value, but its EPS benefit depends on the actual execution price and the priority given to debt reduction rather than headline authorization size.

Near term, the stock is vulnerable to a “good news is priced” reaction after substantial momentum and proximity to its range high. The separation is the principal 1-3 month catalyst only if closing, proceeds, and stranded-cost removal are independently confirmed; the chronology in the supplied materials is internally stale, so this should be verified before underwriting any event-driven trade. Failure to demonstrate sustained volume-led growth—not pricing—or a renewed guidance miss would likely re-open the credibility discount that management is trying to eliminate.

The non-obvious competitive consequence is that improved service speed for regional customers may be more strategically important than large-account wins: it lets IFF participate in emerging brands before they become acquisition targets for KO and other CPG consolidators. Conversely, AI is unlikely to create near-term revenue by itself; it should primarily show up as lower cost-to-serve and better win rates. That favors scaled incumbents including IFF, GIVN, DSFIR and Novonesis (NOVO-B), but makes the thesis dependent on measurable conversion and margin evidence rather than management’s technology narrative.

Key Decisions for Investors

• Initiate a starter long IFF only on confirmation of the separation close and updated capital-allocation schedule; add after the next earnings report if organic growth remains positive and guidance is maintained. Target a 12-18 month rerating versus GIVN/DSFIR, with risk capped by exiting on a guidance cut or evidence that separation costs offset expected savings.
• Use a relative-value pair: long IFF / short DSFIR or GIVN in equal sector-beta-adjusted dollars over 6-12 months. The thesis is closing execution and valuation gaps; stop out if IFF again underperforms peers on organic growth for two consecutive quarters.
• Do not underwrite the buyback as full incremental demand until management discloses completed repurchases, average price, net debt, and post-transaction leverage. Treat those disclosures as a watch-item catalyst rather than a current EPS estimate.
• Monitor North American probiotics and Health & Biosciences capacity utilization through 2025-26. If demand remains weak after capacity comes online, incremental fixed-cost absorption could impair margin expansion; that would favor NOVO-B over IFF within the biosolutions sleeve.